The PPB warns that Cetirizine has no approved use for vaginal tightening.
Kenya’s medicines regulator warns that inserting allergy tablets into the vagina can cause harm and has no proven tightening benefit.
Kenya’s Pharmacy and Poisons Board (PPB) has warned against Cetirizine misuse following viral claims about vaginal tightening. The regulator says inserting the allergy medicine into the vagina is unsafe and scientifically unproven.
The social media trend promotes the tablets as a way to cause dryness and tighten vaginal tissue. However, the board says Cetirizine has no approval for vaginal use or tightening.
In an advisory signed by CEO Dr Ahmed I Mohamed, the PPB explained that Cetirizine treats allergy symptoms. These include allergic rhinitis and urticaria. The medicine is for oral use, and patients should follow a qualified healthcare professional’s directions.
Cetirizine misuse risks irritation and injury
The Pharmaceutical Society of Kenya (PSK) also rejected the claims, explaining that dryness does not mean tightness. Reduced lubrication neither strengthens vaginal muscles nor changes vaginal anatomy.
Instead, reduced lubrication can increase friction, discomfort and tissue injury. The society said manufacturers formulate Cetirizine tablets for swallowing, not contact with delicate vaginal tissue.
The PPB also warned that products not intended for vaginal application can disrupt the vagina’s natural protective environment. This disruption can increase infection risks.
Canadian gynaecologist Dr Jen Gunter similarly warned that inserting oral antihistamines can cause irritation, tissue trauma and small tears. Reduced lubrication can therefore make intercourse painful and damage the vaginal wall’s protective barrier.
Separately, the regulator cautioned against exceeding the recommended oral dose. An overdose can cause excessive sleepiness, dizziness, tiredness, restlessness, confusion, shaking, a rapid heartbeat and difficulty passing urine.
Health ministry plans medicine tracking system
Meanwhile, the Ministry of Health plans to introduce a track-and-trace system following reports of increased demand and panic buying. The system would monitor Cetirizine’s movement from manufacturers to pharmacies and other sales outlets.
The ministry intends to identify unusual purchasing patterns, prevent shortages and curb misuse. It also aims to preserve access for patients who need allergy treatment.
Medical Services Principal Secretary Dr Ouma Oluga warned that even joking online discussions can encourage medicine misuse. PPB Director of Pharmacy Practice Dr Wilfred Ochieng’ also stressed that viral popularity cannot replace scientific evidence.
The PPB urged women with vaginal health concerns to seek professional advice rather than follow unverified online claims. Meanwhile, the PSK advised anyone who has tried inserting the tablets to stop.
Those experiencing pain, bleeding, burning, itching, unusual discharge or fever should seek medical attention, the society said. The public can also report suspected medicine-related side effects through the PPB’s pharmacovigilance portal, mPvERS app, email or telephone.
